Chiome Bioscience Inc. Logo

Chiome Bioscience Inc.

Clinical-stage biotech company developing antibody-based therapeutics.

4583 | T

Overview

Corporate Details

ISIN(s):
JP3205350006
LEI:
Country:
Japan
Address:
渋谷区本町三丁目12番1号

Description

Chiome Bioscience Inc. is a clinical-stage biotechnology company specializing in the research and development of antibody-based therapeutics. The company leverages its proprietary ADLib® system, an innovative antibody generation technology, to discover and develop fully human monoclonal antibodies. Its primary mission is to address unmet medical needs by creating novel antibody drugs. The company's operations focus on the early stages of the drug discovery and development process, including initial research and early-phase clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-03-26 07:20
確認書
Japanese 8.2 KB
2020-11-10 08:02
四半期報告書-第17期第3四半期(令和2年7月1日-令和2年9月30日)
Japanese 160.3 KB
2020-08-11 09:04
四半期報告書-第17期第2四半期(令和2年4月1日-令和2年6月30日)
Japanese 231.0 KB
2020-05-15 08:21
四半期報告書-第17期第1四半期(令和2年1月1日-令和2年3月31日)
Japanese 163.3 KB
2020-04-03 08:28
訂正有価証券報告書-第16期(平成31年1月1日-令和1年12月31日)
Japanese 1.4 MB
2020-03-27 07:18
有価証券報告書-第16期(平成31年1月1日-令和1年12月31日)
Japanese 1.8 MB
2019-11-12 08:06
四半期報告書-第16期第3四半期(2019/07/01-2019/09/30)
Japanese 179.6 KB
2019-08-13 09:24
四半期報告書-第16期第2四半期(2019/04/01-2019/06/30)
Japanese 183.7 KB
2019-05-13 08:38
四半期報告書-第16期第1四半期(2019/01/01-2019/03/31)
Japanese 187.1 KB
2019-03-28 09:02
有価証券報告書-第15期(平成30年1月1日-平成30年12月31日)
Japanese 1.8 MB
2018-11-14 08:01
四半期報告書-第15期第3四半期(2018/07/01-2018/09/30)
Japanese 152.0 KB
2018-08-14 08:13
四半期報告書-第15期第2四半期(2018/04/01-2018/06/30)
Japanese 176.2 KB
2018-05-15 10:02
四半期報告書-第15期第1四半期(2018/01/01-2018/03/31)
Japanese 141.2 KB
2018-03-26 08:02
有価証券報告書-第14期(平成29年1月1日-平成29年12月31日)
Japanese 1.2 MB
2017-11-14 07:02
四半期報告書-第14期第3四半期(2017/07/01-2017/09/30)
Japanese 149.2 KB

Automate Your Workflow. Get a real-time feed of all Chiome Bioscience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chiome Bioscience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chiome Bioscience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.